Want to see OPRX full AI Analyst Report?
Top Page
OptimizeRx
(NASDAQ:OPRX)
Select Model
Select Model
Rating:66Neutral
Price Target:
$9.50
▲(52.24% Upside)
Action:Downgraded
Date:08/17/26
OPRX scores highest on improving financial quality (profitability turnaround, strong cash generation, and modest leverage). The score is moderated by mixed operating signals from the latest earnings update (sharp YoY revenue decline, weaker retention, and visibility/timing risk despite reiterated guidance) and by less compelling valuation (P/E ~35.8 with no dividend). Technically, momentum is strong but appears overbought and still below the 200-day trend, adding near-term pullback risk.
Positive Factors
Strong cash generation and lower leverage
Improving operating cash flow and rapid debt reduction strengthen liquidity and financial flexibility. Lower leverage can reduce refinancing risk and allow more internally generated cash to support product investment or further balance-sheet improvement.
Negative Factors
Revenue contraction and customer concentration
A sharp decline tied to a few large pharmaceutical accounts exposes the business to material customer-specific volatility. Concentration can make revenue recovery less predictable and may pressure margins if lost volume is not replaced.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation and lower leverage
Improving operating cash flow and rapid debt reduction strengthen liquidity and financial flexibility. Lower leverage can reduce refinancing risk and allow more internally generated cash to support product investment or further balance-sheet improvement.
Read all positive factors
OptimizeRx (OPRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$149.93M
Dividend YieldN/A
Average Volume (3M)393.42K
Price to Earnings (P/E)31.6
Beta (1Y)2.05
Revenue Growth-5.82%
EPS GrowthN/A
CountryUS
Employees133
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.24
Shares Outstanding18,835,950
10 Day Avg. Volume233,316
30 Day Avg. Volume393,417
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.67Price Target Upside119.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.94
Revenue Forecast (FY)$97.41M
OptimizeRx Business Overview & Revenue Model
Company Description
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electr...
How the Company Makes Money
OptimizeRx primarily makes money by selling digital engagement and communication services to life sciences (pharmaceutical) companies. Its revenue model is largely B2B and is generated through contracts that allow pharma brands to deliver informat...
OptimizeRx Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: the company delivered an operational beat in Q2, demonstrated margin expansion, launched meaningful product innovations and improved cash/debt metrics, but faced a sizable 30% YoY revenue decline, a dip in net revenue retention to 90%, GAAP loss, and concentration/timing risks tied to a few large customers. Management reiterated full-year guidance and highlighted multiple levers (product launches, mid-market growth, margin optimization, debt reduction) to drive recovery, yet near-term visibility remains uncertain.Positive Updates
Q2 Revenue and Adjusted EBITDA Beat Consensus
Second quarter revenue of $20.5M and adjusted EBITDA of $4.9M both exceeded consensus expectations despite headwinds; adjusted EBITDA demonstrates continued profitability and margin resilience.
Negative Updates
Significant YoY Revenue Decline
Quarterly revenue declined 30% YoY from $29.2M to $20.5M, primarily driven by a limited number of large customers and the absence of one previously material client in the quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Q2 Revenue and Adjusted EBITDA Beat Consensus
Second quarter revenue of $20.5M and adjusted EBITDA of $4.9M both exceeded consensus expectations despite headwinds; adjusted EBITDA demonstrates continued profitability and margin resilience.
Read all positive updates
Company Guidance
OptimizeRx reiterated full‑year 2026 guidance of $95M–$100M in revenue and $21M–$25M in adjusted EBITDA (implying roughly $13M–$17M of EBITDA in H2 given Q2 adj. EBITDA of $4.9M), after reporting Q2 revenue of $20.5M (down 30% YoY from $29.2M), a GAAP net loss of $0.7M ($0.04/sh) and non‑GAAP net income of $3.1M ($0.16/sh); H1 operating cash flow was $8.1M, cash balance $24.1M, outstanding debt was $19.7M at quarter end (with a subsequent $3M paydown to ~$16.7M), term loan at SOFR+2.25%, Q2 expenses fell $5.4M to $20.6M (including $1.7M severance), and key KPIs/growth metrics include average revenue per top‑20 manufacturer of $2.7M, net revenue retention of 90%, revenue per FTE $750k, DAP adoption +30% YoY, AI software +25% YoY, gross margins expected to normalize to the high‑60s/low‑70s, and Q4 expected to be ~35%–40% of FY revenue.OptimizeRx Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 98.65M | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M |
| Gross Profit | 71.17M | 69.27M | 59.38M | 42.90M | 38.97M | 35.64M |
| EBITDA | 15.60M | 16.57M | -8.90M | -21.31M | -9.42M | 2.34M |
| Net Income | 4.60M | 5.13M | -20.11M | -17.57M | -11.44M | 378.08K |
Balance Sheet | ||||||
| Total Assets | 164.32M | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M |
| Cash, Cash Equivalents and Short-Term Investments | 24.10M | 23.36M | 13.38M | 13.85M | 74.14M | 84.68M |
| Total Debt | 19.48M | 26.10M | 33.19M | 36.82M | 234.43K | 327.71K |
| Total Liabilities | 33.23M | 48.62M | 54.17M | 56.82M | 8.54M | 9.61M |
| Stockholders Equity | 131.08M | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M |
Cash Flow | ||||||
| Free Cash Flow | 18.36M | 18.66M | 4.78M | -8.11M | 10.41M | 240.04K |
| Operating Cash Flow | 18.43M | 18.71M | 4.89M | -7.24M | 10.65M | 726.04K |
| Investing Cash Flow | 140.00K | 68.00K | -450.00K | -25.34M | -58.18M | -486.00K |
| Financing Cash Flow | -11.07M | -8.80M | -4.91M | 28.22M | -18.95M | 73.92M |
OptimizeRx Technical Analysis
Neutral
6.24
Price Trends
6.39
Positive
6.16
Positive
8.78
Negative
Market Momentum
0.50
Negative
58.32
Neutral
52.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Neutral. The current price of 6.24 is below the 20-day moving average (MA) of 7.21, below the 50-day MA of 6.39, and below the 200-day MA of 8.78, indicating a neutral trend. The MACD of 0.50 indicates Negative momentum. The RSI at 58.32 is Neutral, neither overbought nor oversold. The STOCH value of 52.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OPRX.
OptimizeRx Risk Analysis
OptimizeRx disclosed 40 risk factors in its most recent earnings report. OptimizeRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OptimizeRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $835.97M | 40.34 | 6.01% | 0.47% | 8.78% | 7.61% | |
74 Outperform | $218.39M | 17.31 | 8.50% | 11.80% | -3.39% | -29.34% | |
66 Neutral | $149.93M | 31.65 | 3.60% | ― | -5.82% | ― | |
63 Neutral | $1.62B | 41.62 | 3.13% | ― | 8.45% | 72.08% | |
59 Neutral | $698.85M | -7.52 | -136.71% | ― | 23.65% | -4.80% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
OPRX
OptimizeRx
7.71
-9.54
-55.30%
HSTM
HealthStream
28.87
1.29
4.66%
OMCL
Omnicell
35.58
1.96
5.83%
SPOK
Spok Holdings
10.31
-5.76
-35.84%
SOPH
SOPHiA GENETICS
8.65
5.04
139.61%
OptimizeRx Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline
Negative
Aug 12, 2026
OptimizeRx Corp. announced on August 7, 2026, that Chief Financial Strategy Officer Edward Stelmakh will step down on December 31, 2026, under a succession plan that elevates Chief Business Officer Andrew D’Silva to Chief Financial Officer ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OptimizeRx Shareholders Expand Equity Plan, Maintain Oversight
Positive
Jun 12, 2026
At its June 9, 2026 annual meeting, OptimizeRx shareholders approved an amendment to the company’s 2021 Equity Incentive Plan, raising the pool of common shares available for equity awards by 1,000,000 to a total of 5,450,000, while rejectin...
Business Operations and StrategyExecutive/Board Changes
OptimizeRx Announces Chief Commercial Officer Transition Agreement
Neutral
Jun 5, 2026
OptimizeRx Corporation disclosed that on May 11, 2026 it agreed with Chief Commercial Officer Theresa Greco to a separation effective June 15, 2026, with a formal Separation and Advisory Agreement signed on June 1, 2026 and scheduled to become eff...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.